![Trulicity (Dulaglutide) Reduces Kidney And Cardiovascular Issues In Diabetics - Thailand Medical News Trulicity (Dulaglutide) Reduces Kidney And Cardiovascular Issues In Diabetics - Thailand Medical News](https://www.thailandmedical.news/uploads/editor/files/trulicity-rx-pads.jpg)
Trulicity (Dulaglutide) Reduces Kidney And Cardiovascular Issues In Diabetics - Thailand Medical News
Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabete
![Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial - The Lancet Diabetes & Endocrinology Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial - The Lancet Diabetes & Endocrinology](https://www.thelancet.com/cms/attachment/e1f51155-083e-4b9c-a610-b644a7d7168b/gr1.gif)
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial - The Lancet Diabetes & Endocrinology
![Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin - Frias - 2019 - Diabetes, Obesity and Metabolism - Wiley Online Library Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin - Frias - 2019 - Diabetes, Obesity and Metabolism - Wiley Online Library](https://dom-pubs.onlinelibrary.wiley.com/cms/asset/aab2433f-dda8-4e11-8910-233de3d939af/dom13764-fig-0002-m.jpg)
Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin - Frias - 2019 - Diabetes, Obesity and Metabolism - Wiley Online Library
![Patient-reported outcomes in patients with type 2 diabetes treated with investigational dulaglutide doses added to metformin (AWARD-11) - Media Centre | EASD Patient-reported outcomes in patients with type 2 diabetes treated with investigational dulaglutide doses added to metformin (AWARD-11) - Media Centre | EASD](https://d2t0unnjxes6lt.cloudfront.net/data/easd/data/talks/939_251765_1/Slide1.jpg)
Patient-reported outcomes in patients with type 2 diabetes treated with investigational dulaglutide doses added to metformin (AWARD-11) - Media Centre | EASD
![TRULICITY 1.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc) TRULICITY 1.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc)](https://www.medicines.org.uk/emc/images/spc/spc~29747~16~image2.png)